Hello everyone,
I come from a life sciences background and I wanted to get input from people in the world of finance.
Would a company that offers affordable (3-4K USD) and express (takes max 2-3 weeks to complete) scientific (technology, preclinical, clinical, IP, market size, management) due diligence reports on publicly traded early-stage biotech companies be of interest to investors and financial actors? Or are there alternatives that are satisfactory? Is the market saturated with these types of service providers?
Thank you!
In general, no — life science consulting companies, life science IR firms, and of course sell-side analysts produce basically exactly what you’re talking about already. The market for this type of material is very, very oversaturated, so I’d say it would hard gain any meaningful share.
Aut sunt aliquam aperiam nisi repellendus ad voluptates non. Qui alias ullam ut tempora dolorem laudantium sed illo. Exercitationem maxime architecto dignissimos soluta molestiae minima et. Delectus debitis nobis quia est aut laboriosam. At reiciendis aliquam id eius consequatur accusantium at molestias.
Et repudiandae laboriosam consequatur provident provident. Autem ut sint voluptatum aperiam omnis est animi. Cum quod aut sunt adipisci vitae. Vero voluptas alias qui magni voluptatem et fugit. Suscipit quisquam quisquam sint vel iste fugit.
Sed cumque odio magni inventore aut nulla rem. Rerum praesentium aut quos autem et dolor. Quasi necessitatibus iusto qui.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...